

Tumor Necrosis Factor- α and Lymphotoxin- α Mediate Myocardial Ischemic Injury via TNF Receptor 1, but Are Cardioprotective When Activating TNF Receptor 2

Yanqing Zhang^{1,9}, Jianli Zhao^{1,9}, Wayne Bond Lau², Li-Yuan Jiao¹, Baojiang Liu¹, Yuexing Yuan², Xiaoliang Wang^{2,3}, Erhe Gao⁴, Walter J. Koch⁴, Xin-Liang Ma^{2*}, Yajing Wang^{2,3*}

1 Department of Anesthesiology, First Affiliated Hospital, Shanxi Medical University, Taiyuan, China, **2** Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America, **3** Department of Physiology, Shanxi Medical University, Taiyuan, China, **4** Center for Translational Medicine, Temple University Medical School, Philadelphia, Pennsylvania, United States of America

Abstract

Objective: This study determines the roles of tumor necrosis factor- α (TNF α) and lymphotoxin- α (LT α) in post-myocardial infarction (post-MI) cardiac injury, and identifies the TNF receptor type responsible for TNF α - and LT α -mediated cardiac injury.

Methods and Results: Adult male wild type (WT), TNF α ^{-/-}, LT α ^{-/-}, TNFR1^{-/-}, and TNFR2^{-/-} mice were subjected to MI via coronary artery occlusion. Functional, histological, and biochemical analyses were performed 1 to 7 days post-MI. In WT mice, MI significantly increased both TNF α and LT α levels in plasma, but in distinct temporal manner. Plasma TNF α peaked 1 day after MI, and decreased toward baseline 3 days after MI. In contrast, plasma LT α became significantly increased 3 days post-MI, and remained elevated thereafter. TNF α deletion significantly improved cardiac function 3 days, but not 7 days, after MI. In contrast, LT α deletion had no effect upon cardiac dysfunction 3 days after MI, but improved cardiac function 7 days after MI. More importantly, knockout of TNFR1 and TNFR2 had opposite effects upon post-MI cardiac dysfunction, which was markedly attenuated by TNFR1 deletion ($P < 0.01$ vs. WT), but exacerbated by TNFR2 deletion ($P < 0.05$ vs. WT).

Conclusion: Our study demonstrates that TNF α and LT α overproduction contribute to early and late cardiac dysfunction after MI, respectively. We provide clear evidence that both TNF α and LT α mediate post-MI cardiac dysfunction via TNFR1 stimulation, whereas TNFR2 activation is cardioprotective against ischemic injury. Simultaneous inhibition of TNF α and LT α or specific TNFR1 function blockade may represent superior cardioprotective approaches over general TNF activity suppression.

Citation: Zhang Y, Zhao J, Lau WB, Jiao L-Y, Liu B, et al. (2013) Tumor Necrosis Factor- α and Lymphotoxin- α Mediate Myocardial Ischemic Injury via TNF Receptor 1, but Are Cardioprotective When Activating TNF Receptor 2. PLoS ONE 8(5): e60227. doi:10.1371/journal.pone.0060227

Editor: Tianqing Peng, University of Western Ontario, Canada

Received: January 20, 2013; **Accepted:** February 23, 2013; **Published:** May 21, 2013

Copyright: © 2013 Zhang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This research was supported by grants from the Natural Science Foundation of China (30900592 and 81170199 to YJW), American Diabetes Association (1-11-JF56 to YJW, 7-11-B5-93 to XLM), and the National Institutes of Health (NIH) (HL-63828, HL-096686 to XLM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The co-author Xin-Liang Ma is a PLOS ONE Editorial Board member. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

* E-mail: Yajing.Wang@jefferson.edu (YW); Xin.Ma@jefferson.edu (XLM)

⁹ These authors contributed equally to this work.

Introduction

Cardiac disease remains a leading cause of mortality worldwide. Although improved reperfusion strategies have decreased death rates after acute myocardial infarction (MI), both incidence and prevalence of post-MI heart failure have increased in recent years [1]. Defining the molecular mechanisms underlying the transition from adaptive to maladaptive remodeling in the post-MI heart, and identifying novel therapeutic strategies capable of blocking/reversing such conversion, are therefore in great need.

TNF α is a pro-oxidative cytokine exerting a wide range of biological activities. Plasma TNF- α levels are significantly increased in patients with cardiovascular disease, particularly myocardial infarction (MI) and heart failure [2]. In vitro experimental studies demonstrate that TNF α suppresses cardiac

contractility [3], provokes myocardial hypertrophy [4], and induces apoptosis in cardiac myocytes [5]. Generally regarded a cardiotoxic molecule, TNF α has been investigated as a target for attenuating cardiovascular injury. Unfortunately, neither soluble antibodies against the TNF receptor [6] nor TNF itself [7] have yielded promising clinical trial results. Mechanisms responsible for the divergent results obtained from experimental models versus clinical patients remain unclear. Recent experimental studies demonstrate that activation of TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2) initiate different/opposite biological effects [8]. However, the roles of TNFR1 and TNFR2 activation by different cytokines produced during different time course after MI remain incompletely understood.

Lymphotoxin- α (LT α , also known as TNF- β) is a member of the TNF family, synthesized primarily by activated T and B lymphocytes [9]. Previous studies demonstrate LT α shares the same membrane receptors as TNF α , exerting biological effect largely via TNFR1 and TNFR2 activation [9]. A recent clinical epidemiological study reveals variations in the gene encoding LT α (thereby affecting its expression and biological function) confers myocardial infarction risk [10]. In vitro experiments demonstrate LT α upregulates adhesion molecule expression [11], and LT α deletion reduces atherosclerosis in mice [12]. However, no direct evidence linking LT α with myocardial ischemic injury currently exists, and the role of LT α in post-MI cardiac injury remains undefined.

Therefore, the aims of the present study were: 1) to compare the role of TNF α and LT α in post-MI cardiac injury; and 2) to identify the TNF α receptor subtype responsible for TNF α - and LT α -mediated cardiac injury.

Materials and Methods

Animals

Wild type (WT, C57BL/6), TNF α gene knockout (TNF α ^{-/-}), LT α gene knockout (LT α ^{-/-}), TNF receptor 1 knockout (TNFR1^{-/-}), and TNF receptor 2 knockout (TNFR2^{-/-}) mice were purchased from Jackson Laboratory (Bar Harbor, ME), and




Figure 1. Time course of post-MI (A) TNF α and (B) LT α production. N = 14–16/group. *P<0.05, **P<0.01 vs. control. doi:10.1371/journal.pone.0060227.g001




Figure 2. Effect of (A) TNF α and (B) LT α gene deletion upon left ventricular ejection fraction (LVEF) determined 3 or 7 days after MI. N = 14–16/group. *P<0.05 vs. WT at the same time point. doi:10.1371/journal.pone.0060227.g002

confirmed by specific primer genotyping. All experiments were performed in adherence with the National Institutes of Health *Guidelines on the Use of Laboratory Animals*, and were approved by the Thomas Jefferson University Committee on Animal Care.

Experimental Protocols

Male adult mice were anesthetized with 2% isoflurane. Myocardial infarction (MI) was produced by temporarily exteriorizing the heart via left thoracic incision, and placing a 6–0 silk suture slipknot around the left anterior descending coronary artery [13]. Sham-operated control mice (sham MI) underwent the same surgical procedures, except the suture placed under the left coronary artery was not tied. Plasma TNF α , LT α , cardiac function, and cardiac injury were determined as described below.

Determination of Plasma TNF α and LT α Concentrations

After 1, 3, or 7 days of MI or sham MI, animals were re-anesthetized (2% isoflurane). Left ventricular blood was centrifuged, yielding plasma. Plasma TNF α and LT α concentrations were determined by mouse TNF α and LT α ELISA kits (BioLegend, San Diego, CA) per manufacturer's instructions.

Determination of Cardiac Function

After 3 or 7 days of MI or sham MI, animals were re-anesthetized. Parasternal short axis m-mode images of the murine left ventricle, obtained via VisualSonics 770 machine with 25-MHz linear transducer, recorded heart rate (HR), end-




Figure 3. Effect of TNFR gene deletion upon cardiac function 3 days following MI. Genetic deletion of TNFR1, but not TNFR2, significantly attenuated post-MI (at day 3) cardiac dysfunction, as determined by left ventricular ejection fraction (LVEF, B) and fractional shortening (FS, A). N = 15–16/group. ** $P < 0.01$ vs. own sham MI control; ^{*} $P < 0.05$, ^{\$\$} $P < 0.01$ vs. WT at the same time point. doi:10.1371/journal.pone.0060227.g003

diastolic dimension (EDD), end-systolic dimension (ESD), and anterior/posterior wall thickness. All echocardiographic parameters were averaged over 10–20 cardiac cycles. Calculated values included left ventricular ejection fraction (LVEF), fractional shortening (FS), and average wall thickness. At the end of 7-day observation period, cardiac function was also determined by left ventricular (LV) catheterization (1.2-Fr micromanometer, Millar Instruments, Houston, TX) prior to animal sacrifice. Echocardiography and LV catheterization have been described in detail previously [14;15].

Measurement of Infarct Size

Hearts were preserved in 10% formalin overnight, and embedded in paraffin. Cardiac regions proximal of the ligated coronary artery (including left and right atria) were dissected away. Distal remaining cardiac portions were transversely sliced from




Figure 4. Effect of TNFR gene deletion upon cardiac function 7 days following MI. TNFR1 gene deletion significantly improved cardiac function 7 days post-MI, as evidenced by reduced left ventricular end diastolic pressure (LVEDP, A) and increased $\pm dP/dt_{max}$ (B, C). In contrast, TNFR2 gene deletion further exacerbated cardiac dysfunction (B, C). N = 14–15/group. * $P < 0.05$, ** $P < 0.01$ vs. own sham MI control; ^{*} $P < 0.05$, ^{\$\$} $P < 0.01$ vs. WT at the same time point. doi:10.1371/journal.pone.0060227.g004

apex to base, in 6 μm thick sections, with 900 μm between each section. All sections were mounted upon glass slides and stained with Masson trichrome stain (MarketLab Inc, Caledonia, MI). All histological sections were examined via Olympus BX51 microscope (2 \times objective lens). Images were captured via QIMAGINE CCD camera, utilizing IPLab 4.0 software. The LV myocardial midline was drawn centrally between the epicardial and endocardial surfaces. Midline circumference was measured. Infarct size was calculated by dividing midline infarct lengths (Masson blue staining) by midline circumferences, and multiplying by 100%. Results from all slides obtained in the same heart were averaged, and counted as $n = 1$.

Table 1. Plasma TNF α and LT α Levels in Different Groups Investigated.

Post-MI(d)	TNF α (pg/ml)				LT α (pg/ml)			
	0	1	3	7	0	1	3	7
WT	36 \pm 2.9	72 \pm 3.9**	68 \pm 4.1**	47 \pm 3.2*	16.3 \pm 2.1	24.2 \pm 1.4	64.9 \pm 3.9**	60.6 \pm 4.2**
TNFR1KO	33 \pm 3.1	66 \pm 3.8**	65 \pm 4.2**	46 \pm 3.9*	15.7 \pm 2.2	23.5 \pm 1.8	66.4 \pm 2.9**	59.7 \pm 3.9**
TNFR2KO	37 \pm 3.9	81 \pm 4.2**	79 \pm 3.8**	53 \pm 3.1*	16.8 \pm 2.4	25.3 \pm 1.9	67.4 \pm 3.1**	60.9 \pm 4.3**

WT = Wild type; TNFR1KO = TNF receptor 1 knockout; TNFR2KO = TNF receptor 2 knockout; N = 14–16/group. *P<0.05, **P<0.01 vs. day 1 post-MI.
doi:10.1371/journal.pone.0060227.t001




Figure 5. Effect of TNFR gene deletion upon infarct size following MI. TNFR1 and TNFR2 gene deletion had opposite effects upon infarct size (A) and interstitial fibrosis in remote non-ischemic regions (B). N = 9–11/group. [§]P<0.05 vs. WT. All results were obtained from animals subjected to 7 days of MI.
doi:10.1371/journal.pone.0060227.g005

Histological Analysis of Myocardial Fibrosis

Each heart was processed as described above, and stained with Masson's trichrome 2000 stain. Slides were examined via Olympus IX51 microscope (20 \times objective lens). 5 remote, non-ischemic area images were captured. Collagen-positive areas were calculated by Image IPlab 4.0 software. Percent fibrosis was expressed as the ratio of fibrotic area (blue) to total LV area [16]. Average blue area percentage was calculated in at least 5 different hearts.

Statistical Analysis

All values in the text and figures are presented as means \pm SEM of *n* independent experiments. Data were subjected to one or two-way (where appropriate) ANOVA followed by Bonferoni correction for *post-hoc* test. Probabilities of 0.05 or less were considered statistically significant.

Results

Plasma TNF α and LT α Significantly Increase After MI, but Follow Different Time Courses

Plasma TNF α levels swiftly peaked 1 day after MI, and gradually reduced thereafter. In contrast, plasma LT α rise did not significantly occur until 3 days after MI, but remained significantly greater than control 7 days after MI (Figure 1).

Genetic Deletion of TNF α and LT α Exerted Distinct Cardioprotection at Different Time Course After MI

TNF α knockout had no significant effect upon LV function during basal conditions (Figure 2A). However, 3 days after MI, TNF α knockout mice exhibited significantly improved cardiac function compared to WT. However, TNF α knockout was only transiently cardioprotective. 7 days after MI, no difference in LV function was observed between TNF α knockout mice and control. LT α knockout did not affect LVEF before MI, and only slightly increased LVEF 3 days after MI ($P>0.05$). However, LT α knockout mice did not exhibit continuous deterioration of cardiac function, as observed in WT animals. 7 days after MI, LVEF was significantly greater in LT α knockout mice compared to WT (Figure 2B).

TNFR1 and TNFR2 Knockout had Opposite Effect Upon Post-MI Cardiac Dysfunction

Having demonstrated that TNF α and LT α knockout improved cardiac function at different time courses following MI, we further determined the contribution of TNF α receptor types (TNFR1 and TNFR2) to cardiac injury mediated by TNF α /LT α . Plasma TNF α and LT α concentration, as well as the effect of TNFR1 and TNFR2 deletion upon post-MI cardiac function was determined via echocardiography and left ventricular catheterization, 3 and

7 days after MI respectively. Knockout either TNFR1 or TNFR2 had no significant impact on plasma TNF α and LT α before or after MI (Table 1). In sham MI control animals, no significant difference in cardiac function between groups was observed (Figures 3 and 4, left three bars). 3 days post-MI, LVEF and FS were significantly decreased in all three groups compared to respective control (* P <0.05, ** P <0.01). However, cardiac dysfunction was significantly attenuated ($^{\$}P$ <0.05, $^{\$\$}P$ <0.01) in TNFR1 $^{-/-}$ mice compared WT (Figure 4). Mildly poorer cardiac dysfunction was observed in TNFR2 $^{-/-}$ mice, but not to statistically significant degree compared to WT (Figure 3).

Consistent with echocardiographic results obtained 3 days post-MI, cardiac dysfunction was significantly attenuated in TNFR1 $^{-/-}$ mice compared to WT ($^{\$\$}P$ <0.01) 7 days post-MI, evidenced by decreased LVEDP (Figure 4A) and increased $\pm dP/dt_{max}$ (Figure 4B, C). Although no significant difference in LVEDP between TNFR2 $^{-/-}$ and WT was observed, TNFR2 $^{-/-}$ mice exhibited significantly decreased $\pm dP/dt_{max}$ ($^{\$}P$ <0.05).

TNFR1 and TNFR2 Knockout had Opposite Effects upon Infarct Size and Pathological Remodeling

To determine the impact of TNFR1 and TNFR2 deletion upon MI injury at the cellular level, two additional outcomes were measured 7 days after MI. Myocardial infarct size was significantly reduced in TNFR1 $^{-/-}$ mice compared to WT ($^{\$}P$ <0.05, Figure 5A). In contrast, TNFR2 deletion further increased infarct size ($^{\$}P$ <0.05). Moreover, TNFR1 and TNFR2 deletion had opposite effects upon interstitial fibrosis in non-ischemic remote regions (Figure 5B), as interstitial fibrosis was significantly reduced in TNFR1 $^{-/-}$ mice, but exacerbated in TNFR2 $^{-/-}$ mice ($^{\$}P$ <0.05).

Discussion

We present several important observations in the current study. We provide direct evidence that TNF α and LT α contribute to post-MI cardiac injury via distinctive time courses. TNF α is a prominent element within the “cytokine hypothesis” of myocardial ischemic heart disease [2]. Transgenic mice with cardiac-specific overexpression of TNF α develop cardiac dilatation, interstitial infiltrates, abnormal calcium homeostasis, increased apoptosis, extracellular matrix remodeling, ventricular arrhythmias, and early death [17]. Moreover, many experimental studies have demonstrated that inhibiting TNF α production or blocking TNF α -initiated intracellular signaling attenuates ischemic myocardial injury [18]. However, anti-cytokines have not proven clinically efficacious in chronic heart failure patients. Such disparity illustrates our incomplete understanding of TNF α within heart failure pathophysiology. The current study confirms TNF α overproduction occurs following MI in burst fashion, rising quickly, but lasting transiently. In contrast, no significant LT α overproduction develops until 3 days after MI. However, plasma LT α concentration remained significantly greater than control even 7 days after MI. More importantly, TNF α -knockout significantly improved cardiac function during the early phase of MI, whereas LT α -knockout selectively augmented cardiac function during the late stage of MI. These results possibly explain the efficacy discrepancy of anti-TNF α treatment post-MI between acute experimental models and chronic clinical heart failure patients.

LT α , a member of the TNF family, is synthesized primarily by activated T and B lymphocytes [9]. It is expressed in either secreted or membrane-bound form, each exhibiting different affinity for various receptors. The secreted soluble homotrimeric

form binds to both TNFR1 and TNFR2 receptors with high affinity, whereas the transmembrane heterotrimeric form (one LT α plus two LT β) selectively binds the LT β receptor (LT β R) with high specificity. LT α mediates various inflammatory, immunostimulatory, and antiviral responses, influences cell death or differentiation, and provides a communicative link between lymphocytes and stromal cells [9]. Several genetic and clinical studies demonstrate that variations in the gene encoding LT α (consequently affecting its expression and biological function) contribute to the risk of coronary artery disease, myocardial infarction, aortic aneurysm formation, and cerebral infarction [19;20]. Recent clinical studies demonstrate LT α gene variability is also associated with metabolic syndrome features, including increased C-reactive protein, hyperinsulinemia, and dyslipidemia [21]. Our current study demonstrates for the first time that LT α knockout significantly improves cardiac function 7 days after MI, providing direct evidence that LT α overproduction plays a causative role in post-MI cardiac injury. Mechanisms responsible for LT α -induced cardiac injury are likely complex and multifactorial. Previous in vitro studies associate LT α -induced gene expression with signal transduction, cell adhesion and chemoattraction, such as the nuclear factor of kappa light polypeptide gene enhancer in B-cells (NF κ B), endothelial adhesion molecule 1 (E-Selectin), vascular cell adhesion molecule 1 (VCAM1), and monocyte chemoattractant protein 1 (MCP1) [11]. As inflammation plays a significant role in post-MI pathologic remodeling, inhibiting LT α may attenuate the inflammatory response, preserving cardiac function.

T lymphocytes are pathogenic during post-MI injury. Deletion of recombination-activating gene (RAG1 $^{-/-}$), a protein necessary for immunoglobulin and T-cell receptor gene recombination, significantly reduced infarct size after MI/R [22]. This protective effect was reversed by reconstitution of RAG1 $^{-/-}$ mice by adoptive transfer with CD4 $^{+}$ T cells. Moreover, CD4 $^{+}$ depleted mice, but not CD8 $^{+}$ depleted mice, have significantly decreased infarct size compared to control mice [22], further supporting the deleterious role of CD4 $^{+}$ T cells during post-MI injury. As LT α is synthesized primarily by activated T lymphocytes, our current study provides data consistent with such lines of evidence, and suggests blockade of LT α overproduction from activated T cells may be, at least partly, responsible for the cardioprotection observed in the RAG1 $^{-/-}$ and CD4 $^{+}$ T-cell depleted state.

Emerging evidence indicates that TNFR2 activation by TNF α exerts opposite biologic effects as TNFR1 activation. Greater TNF α concentrations and cardiomyocyte TNFR1 activation are detrimental, whereas lower TNF α concentrations and cardiomyocyte TNFR2 activation are protective. TNFR1 $^{-/-}$ reduces apoptosis, attenuates hypertrophy, improves contractile function, promotes angiogenesis, and improves survival [23–26]. In contrast, TNFR2 $^{-/-}$ exacerbates MI injury [23;25–27]. Recent studies confirm the opposite effects of TNFR1/TNFR2 activation during MI injury result from their opposing regulatory effects upon NF- κ B. Specifically, TNFR1 deletion diminishes MI-induced NF- κ B activation, whereas TNFR2 deletion augments MI-induced NF- κ B activation [26]. Additionally, TNF α effects may depend upon its concentration, duration of exposure, and localization. Therefore, it is not surprising that clinical chronic heart failure trials, employing compounds antagonizing TNF α (including the TNF α -binding antibody infliximab and the soluble recombinant TNF α -receptor etanercept) revealed disappointing results [28]. The current study supports the opposite roles of TNFR1 and TNFR2 in post-MI injury. More importantly, we demonstrate that TNF α knockout only improves cardiac function during the early post-MI phase, whereas LT α knockout only improves late post-MI cardiac function. TNFR1

knockout protects against injury during the entire 7-day post-MI period. Our results suggest both TNF α and LT α mediate cardiac injury via TNFR1 activation.

In summary, the current study provides the first direct evidence that LT α overproduction post-MI contributes to MI/R injury via TNFR1 activation. In contrast, TNFR2 activation protects against MI/R injury. Simultaneous inhibition of TNF α and LT α or specific

TNFR1 function blockade may represent superior cardioprotective approaches over general TNF activity suppression.

Author Contributions

Conceived and designed the experiments: WK XM YW. Performed the experiments: YZ JZ LJ BL YY XW EG. Analyzed the data: YZ JZ LJ YY XW. Wrote the paper: YZ WL XM YW.

References

- Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, et al. (2011) Heart disease and stroke statistics – 2011 update: a report from the American Heart Association. *Circulation* 123: e18–e209.
- Kleinbongard P, Heusch G, Schulz R (2010) TNF α in atherosclerosis, myocardial ischemia/reperfusion and heart failure. *Pharmacol Ther* 127: 295–314.
- Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, et al. (1992) Negative inotropic effects of cytokines on the heart mediated by nitric oxide. *Science* 257: 387–389.
- Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, et al. (1993) Cellular basis for the negative inotropic effects of tumor necrosis factor- α in the adult mammalian heart. *J Clin Invest* 92: 2303–2312.
- Li S, Jiao X, Tao L, Liu H, Cao Y, et al. (2007) Tumor necrosis factor- α in mechanic trauma plasma mediates cardiomyocyte apoptosis. *Am J Physiol Heart Circ Physiol* 293: H1847–H1852.
- Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, et al. (2004) Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etorcept Worldwide Evaluation (RENEWAL). *Circulation* 109: 1594–1602.
- Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT (2003) Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor- α , in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. *Circulation* 107: 3133–3140.
- Defer N, Azroyan A, Pecker F, Pavoine C (2007) TNFR1 and TNFR2 Signaling Interplay in Cardiac Myocytes. *J Biol Chem* 282: 35564–35573.
- Naoum JJ, Chai H, Lin PH, Lumsden AB, Yao Q, Chen C (2006) Lymphotoxin- α and cardiovascular disease: clinical association and pathogenic mechanisms. *Med Sci Monit* 12: RA121–RA124.
- Ozaki K, Inoue K, Sato H, Iida A, Ohnishi Y, et al. (2004) Functional variation in LGALS2 confers risk of myocardial infarction and regulates lymphotoxin- α secretion in vitro. *Nature* 429: 72–75.
- Suna S, Sakata Y, Sato H, Mizuno H, Nakatani D, et al. (2008) Up-regulation of cell adhesion molecule genes in human endothelial cells stimulated by lymphotoxin α : DNA microarray analysis. *J Atheroscler Thromb* 15: 160–165.
- Schreyer SA, Vick CM, LeBoeuf RC (2002) Loss of lymphotoxin- α but not tumor necrosis factor- α reduces atherosclerosis in mice. *J Biol Chem* 277: 12364–12368.
- Wang Y, Tao L, Yuan Y, Lau WB, Li R, et al. (2009) Cardioprotective effect of adiponectin is partially mediated by its AMPK-independent antinflammatory action. *Am J Physiol Endocrinol Metab* 297: E384–E391.
- Tao L, Gao E, Bryan NS, Qu Y, Liu HR, et al. (2004) Cardioprotective effects of thioredoxin in myocardial ischemia and reperfusion: Role of S-nitrosation. *PNAS* 101: 11471–11476.
- Tao L, Gao E, Jiao X, Yuan Y, Li S, et al. (2007) Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrosative stress. *Circulation* 115: 1408–1416.
- He W, Zhang L, Ni A, Zhang Z, Mirotso M, et al. (2010) Exogenously administered secreted frizzled related protein 2 (Sfrp2) reduces fibrosis and improves cardiac function in a rat model of myocardial infarction. *Proc Natl Acad Sci U S A* 107: 21110–21115.
- Kubota T, McTiernan CF, Frye CS, Slawson SE, Lemster BH, et al. (1997) Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor- α . *Circ Res* 81: 627–635.
- Kubota T, Bounoutas GS, Miyagishima M, Kadokami T, Sanders VJ, et al. (2000) Soluble tumor necrosis factor receptor abrogates myocardial inflammation but not hypertrophy in cytokine-induced cardiomyopathy. *Circulation* 101: 2518–2525.
- Schulz S, Schagdarsurengin U, Rehfeld D, Suss T, Werdan K, et al. (2006) Genetic impact of TNF- β on risk factors for coronary atherosclerosis. *Eur Cytokine Netw* 17: 148–154.
- Jang Y, Koh SJ, Kim OY, Kim BK, Choi D, et al. (2007) Effect of the 252A>G polymorphism of the lymphotoxin- α gene on inflammatory markers of response to cigarette smoking in Korean healthy men. *Clin Chim Acta* 377: 221–227.
- Jang Y, Kim HJ, Koh SJ, Hyun YJ, Chae JS, et al. (2007) Lymphotoxin- α gene 252A>G and metabolic syndrome features in Korean men with coronary artery disease. *Clin Chim Acta* 384: 124–128.
- Yang Z, Day YJ, Toufektsian MC, Xu Y, Ramos SI, et al. (2006) Myocardial infarct-sparing effect of adenosine A2A receptor activation is due to its action on CD4+ T lymphocytes. *Circulation* 114: 2056–2064.
- Higuchi Y, McTiernan CF, Frye CB, McGowan BS, Chan TO, et al. (2004) Tumor necrosis factor receptors 1 and 2 differentially regulate survival, cardiac dysfunction, and remodeling in transgenic mice with tumor necrosis factor- α -induced cardiomyopathy. *Circulation* 109: 1892–1897.
- Monden Y, Kubota T, Inoue T, Tsutsumi T, Kawano S, et al. (2007) Tumor necrosis factor- α is toxic via receptor 1 and protective via receptor 2 in a murine model of myocardial infarction. *Am J Physiol Heart Circ Physiol* 293: H743–H753.
- Kishore R, Tkebuchava T, Sasi SP, Silver M, Gilbert HY, et al. (2011) Tumor necrosis factor- α signaling via TNFR1/p55 is deleterious whereas TNFR2/p75 signaling is protective in adult infarct myocardium. *Adv Exp Med Biol* 691: 433–448.
- Hamid T, Gu Y, Ortines RV, Bhattacharya C, Wang G, et al. (2009) Divergent Tumor Necrosis Factor Receptor-Related Remodeling Responses in Heart Failure: Role of Nuclear Factor- κ B and Inflammatory Activation. *Circulation* 119: 1386–1397.
- Goukassian DA, Qin G, Dolan C, Murayama T, Silver M, et al. (2007) Tumor necrosis factor- α receptor p75 is required in ischemia-induced neovascularization. *Circulation* 115: 752–762.
- Schulz R, Heusch G (2009) Tumor Necrosis Factor- α and Its Receptors 1 and 2: Yin and Yang in Myocardial Infarction? *Circulation* 119: 1355–1357.